// App-Quantinova.ai

9510 : Neoadjuvant (neo) immune checkpoint blockade (ICB) in patients (Pts) with high-risk resectable metastatic melanoma (MM).

Researchers

Presenter

  • Rodabe Navroze Amaria

Principal Investigators

  • Hussein Abdul-Hassan Tawbi

  • Michael A. Davies

  • Merrick I. Ross

  • Isabella Claudia Glitza

  • Janice N. Cormier

  • Carol M. Lewis

  • Wen-Jen Hwu

  • Ehab Y. Hanna

  • Adi Diab

  • Michael K.K. Wong

  • Richard Eldon Royal

  • Neil D. Gross

  • Randal S. Weber

  • Stephen Yenzen Lai

  • Richard A. Ehlers

  • Elizabeth M. Burton

  • Michael T. Tetzlaff

  • Jennifer Ann Wargo

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • The University of Texas, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • 1.MD Anderson Cancer Center, Houston, TX

  • The University of Texas MD Anderson Cancer Center, Department of Neurosurgery, Houston, TX

  • Department of Breast Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • Randomized

  • Non-Comparative

Phase

  • II

Study Id's

  • NCT02519322

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved